These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2480428)

  • 21. Down's syndrome: current screening techniques.
    White RS
    South Med J; 1989 Dec; 82(12):1483-6. PubMed ID: 2480649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects.
    Jaques AM; Collins VR; Haynes K; Sheffield LJ; Francis I; Forbes R; Halliday JL
    J Med Screen; 2006; 13(1):8-13. PubMed ID: 16569299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are Down syndrome fetuses detected through maternal serum screening similar to those remaining undetected?
    Christiaens GC; Hagenaars AM; Akkerman C; De France HF
    Prenat Diagn; 1996 May; 16(5):437-42. PubMed ID: 8844002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of MSAFP screening on genetic services, 1984-1986.
    Greenberg F
    Am J Med Genet; 1988 Sep; 31(1):223-30. PubMed ID: 2464932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Proposed normal values for alpha fetoprotein in maternal serum for the detection of neural tube closure defects and Down syndrome. Preliminary study].
    Carreras de Paz JJ; Silva Mendoza JM; Violante Diaz M; Cerrillo Hinojosa M; Ahued Ahued JR
    Ginecol Obstet Mex; 1991 Aug; 59():261-4. PubMed ID: 1722478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maternal serum screening for neural tube defects and Down's syndrome.
    Robertson EF
    Med J Aust; 1991 Sep; 155(5):349. PubMed ID: 1832734
    [No Abstract]   [Full Text] [Related]  

  • 27. [Specificity of biochemical markers of pregnancy second trimester].
    Salazar López R; Ibarra Gallardo AL; Iduma Meléndrez M; Leyva Bojórquez R
    Ginecol Obstet Mex; 2007 Oct; 75(10):608-14. PubMed ID: 18800579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies.
    Frishman GN; Canick JA; Hogan JW; Hackett RJ; Kellner LH; Saller DN
    Obstet Gynecol; 1997 Jul; 90(1):98-101. PubMed ID: 9207822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal alpha-fetoprotein screening for Down's syndrome.
    Pueschel SM
    N Engl J Med; 1987 Aug; 317(6):376-8. PubMed ID: 2439910
    [No Abstract]   [Full Text] [Related]  

  • 30. Insulin-dependent diabetes mellitus and prenatal screening results: current experience from a regional screening programme.
    Crossley JA; Berry E; Aitken DA; Connor JM
    Prenat Diagn; 1996 Nov; 16(11):1039-42. PubMed ID: 8953638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prenatal biochemical diagnostics of inborn developmental defects.
    Malbohan I; Fialová L; Mikulíková L; Hájek Z
    Sb Lek; 1994; 95(4):277-83. PubMed ID: 8867698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Maternal serum screening for congenital abnormalities and Down syndrome in Sønderjylland County. Eight years of experience].
    Christiansen M; Petersen PL; Permin M; Larsen LA; Nørgaard-Pedersen B
    Ugeskr Laeger; 1999 Dec; 161(50):6928-34. PubMed ID: 10643380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refinements in managing maternal weight adjustment for interpreting prenatal screening results.
    Neveux LM; Palomaki GE; Larrivee DA; Knight GJ; Haddow JE
    Prenat Diagn; 1996 Dec; 16(12):1115-9. PubMed ID: 8994247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fetal oculocerebrorenal syndrome of Lowe associated with elevated maternal serum and amniotic fluid alpha-fetoprotein levels.
    Miller RC; Wolf EJ; Gould M; Macri CJ; Charnas LR
    Obstet Gynecol; 1994 Jul; 84(1):77-80. PubMed ID: 7516514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of normal MSAFP screening on maternal age for genetic amniocentesis.
    Ganiats TG; Berry CC; Fullerton JT
    J Clin Epidemiol; 1990; 43(11):1143-8. PubMed ID: 1700812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maternal serum markers for Down's syndrome pregnancies.
    Chew S; Anandakumar C; Ratnam SS
    Singapore Med J; 1995 Aug; 36(4):417-23. PubMed ID: 8919160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current techniques of prenatal screening for Down syndrome.
    Cardwell MS; Gay JW
    Mo Med; 1990 May; 87(5):295-7. PubMed ID: 1694954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prenatal diagnosis of open neural tube defects using the amniotic fluid acetylcholinesterase assay.
    Milunsky A; Sapirstein VS
    Obstet Gynecol; 1982 Jan; 59(1):1-5. PubMed ID: 6176922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High maternal serum alpha-fetoprotein levels during the 2nd trimester of pregnancy: diagnostic approach.
    Periti E; Cariati E; Brizzi L; Nannini R; Paladini S
    J Nucl Med Allied Sci; 1989; 33(3 Suppl):81-4. PubMed ID: 2480430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.